Clinical Factors Associated With Dose Escalation of Solifenacin for the Treatment of Overactive Bladder in Real Life Practice
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To determine the baseline clinical characteristics associated with dose escalation of solifenacin in patients with overactive bladder (OAB). Methods: We analyzed the data of patients with OAB (micturition frequency≥8/day and urgency≥1/day) who were treated with solifenacin and followed up for 24 weeks. According to our department protocol, all the patients kept voiding diaries, and OAB symptom scores (OABSS) were monitored at baseline and after 4, 12, and 24 weeks of solifenacin treatment. Results: In total, 68 patients (mean age, 60.8±10.0 years) were recruited. The dose escalation rate by the end of the study was 41.2%, from 23.5% at 4 weeks and 17.6% at 12 weeks. At baseline, the dose escalator group had significantly more OAB wet patients (53.6% vs. 20.0%) and higher total OABSS (10.2±2.4 vs. 7.9±3.5, P=0.032) than the nonescalator group. OAB wet (odds ratio [OR], 4.615; 95% confidence interval [CI], 1.578–13.499; P<0.05) and total OABSS (OR, 1.398; 95% CI, 1.046–1.869; P<0.05) were found to be independently associated with dose escalation. Conclusions: Patients who have urgency urinary incontinence and high total OABSS have a tendency for dose escalation of solifenacin.
Abstract
Purpose: To determine the baseline clinical characteristics associated with dose escalation of solifenacin in patients with overactive bladder (OAB). Methods: We analyzed the data of patients with OAB (micturition frequency≥8/day and urgency≥1/day) who were treated with solifenacin and followed up for 24 weeks. According to our department protocol, all the patients kept voiding diaries, and OAB symptom scores (OABSS) were monitored at baseline and after 4, 12, and 24 weeks of solifenacin treatment. Results: In total, 68 patients (mean age, 60.8±10.0 years) were recruited. The dose escalation rate by the end of the study was 41.2%, from 23.5% at 4 weeks and 17.6% at 12 weeks. At baseline, the dose escalator group had significantly more OAB wet patients (53.6% vs. 20.0%) and higher total OABSS (10.2±2.4 vs. 7.9±3.5, P=0.032) than the nonescalator group. OAB wet (odds ratio [OR], 4.615; 95% confidence interval [CI], 1.578–13.499; P<0.05) and total OABSS (OR, 1.398; 95% CI, 1.046–1.869; P<0.05) were found to be independently associated with dose escalation. Conclusions: Patients who have urgency urinary incontinence and high total OABSS have a tendency for dose escalation of solifenacin.
참고문헌 (17)
- Abrams P, "The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society", Neurourol Urodyn, 21, pp.167~178 (2002)
- Lee YS, "Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study", World J Urol, 29, pp.185~190 (2011)
- Irwin DE, "Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder", Eur Urol, 56, pp.14~20 (2009)
- Liberman JN, "Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey", Urology, 57, pp.1044~1050 (2001)
- MacDiarmid SA, "Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached?", BJU Int, 99(Suppl 3), pp.8~12 (2007)
- Cardozo L, "Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial", BJU Int, 102, pp.1120~1127 (2008)
- Abrams P, "Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis", Eur Urol, 48, pp.483~487 (2005)
- Chapple CR, "A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial", Eur Urol, 48, pp.464~470 (2005)
- Karram MM, "Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial", Urology, 73, pp.14~18 (2009)
- 정성진, "Korean Version of the Overactive Bladder Symptom Score Questionnaire: Translation and Linguistic Validation", International Neurourology Journal, 15(3), pp.135~142 (2011), 대한배뇨장애요실금학회
- Coyne KS, "Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts", Urology, 68(2 Suppl), pp.9~16 (2006)
- Andersson KE, "Antimuscarinics for treatment of overactive bladder", Lancet Neurol, 3, pp.46~53 (2004)
- Chapple CR, "Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome", BJU Int, 104, pp.960~967 (2009)
- Cardozo L, "Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE)", BJU Int, 111, pp.804~810 (2013)
- Serati M, "Risk factors for the failure of antimuscarinic treatment with solifenacin in women with overactive bladder", Urology, 82, pp.1044~1048 (2013)
- Chapple CR, "The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis", Eur Urol, 54, pp.543~562 (2008)
- Wyndaele JJ, "Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study", BJU Int, 107, pp.603~611 (2011)